The blood ketone meter is a handheld medical device used to test the levels of ketone bodies such as β-hydroxybutyrate in human blood. This device is important for monitoring ketone levels in conditions like diabetes as abnormally high ketone levels or ketoacidosis indicate poor blood sugar control and may require immediate medical treatment. The growing prevalence of diabetes worldwide has increased the demand for continuous glucose monitoring and devices like blood ketone meters help manage the disease condition more effectively. The global blood ketone meter market is estimated to be valued at US$ 421.41 billion in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The rising prevalence of diabetes especially type 1 diabetes remains a key factor driving the growth of the blood ketone meter market. As per the International Diabetes Federation, in 2019 there were approximately 463 million adults aged between 20-79 years living with diabetes and by 2045 this number is projected to rise to 700 million. Maintaining optimal blood glucose and ketone levels is crucial for people with diabetes to prevent complications. Blood ketone meters provide an easy and convenient way to frequently monitor ketones levels at home, facilitating timely treatment decisions. With increasing awareness about diabetes management, the demand for point-of-care ketone monitoring devices like blood ketone meters is expected to grow significantly over the forecast period.
Porter’s Analysis
Threat of new entrants: The market requires large financial investment in Research and Development which poses significant barriers for new companies. However, advancements in technology may lower these barriers over time.
Bargaining power of buyers: There exists a large pool of key players in the market providing alternatives to buyers. However, strong brand loyalty allow companies to exercise some pricing power.
Bargaining power of suppliers: Key raw materials and components have few substitute options, allowing key suppliers to influence prices. However, established players try to diversify supplier base to mitigate this risk.
Threat of new substitutes: Alternatives technologies offer some substitutes but none perfectly replace all benefits making demand for blood ketone meters resilient.
Competitive rivalry: Large player differentiate through quality, reliability and reputation keeping rivalry high.
SWOT Analysis
Strengths: Established brands, technological advancements improving product features, growing awareness about managing diabetes and ketosis.
Weaknesses: High R&D costs, pricing pressure from alternatives, reliance on few suppliers for key materials.
Opportunities: Expanding into emerging markets, remote monitoring solutions, diversifying product offerings.
Threats: Supply chain disruptions, stringent regulations, alternative technologies.
Key Takeaways
The Global Blood Ketone Meter Market Share is expected to witness high growth over the forecast period of 2024 to 2031. The market size for 2024 is US$ 421.41 Bn with a CAGR of around 12%.
Regional analysis: North America currently dominates the market due to well established healthcare infrastructure and growing diabetes cases. Asia Pacific is expected to be the fastest growing region supported by rising healthcare spending, growing patient base and increasing adoption of advanced technologies.
Key players operating in the blood ketone meter market are Arthrex, Inc., Stryker Corporation, Johnson and Johnsons Ltd., Zimmer Biomet Holdings Inc., Terumo Corporation, Glofinn Oy, Medira Ltd., Regen Lab S.A., CollPlant, Generex Biotechnology Corporation, Estar Technologies Ltd., Dr. PRP America, Cesca Therapeutics, Inc., Arteriocyte Medical Systems, Harvest Technologies Corp. Arthrex and Stryker are the market leaders due to their diverse product portfolio and global footprint.
Get More Insights Here
https://www.trendingwebwire.com/blood-ketone-meter-market-size-share-growth-outlook-2023/
Comments
0 comment